

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **November 7, 2016**

BIOTRICITY INC.

(Exact Name of Registrant as Specified in Its Charter)

<u>Nevada</u> (State or Other Jurisdiction of Incorporation or Organization)	<u>333-201719</u> (Commission File Number)	<u>47-2548273</u> (IRS Employer Identification No.)
<u>75 International Blvd., Suite 300</u> Toronto, ON (Address of Principal Executive Offices)		<u>M9W 6L9</u> (Zip Code)

Registrant's Telephone Number, Including Area Code: (416) 214-3678

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events

On November 7, 2016, Biotricity, Inc., a Nevada corporation (the “Registrant”), released a letter to shareholders to provide an update on the Registrant’s progress.

A copy of the letter is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits. The exhibit listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K:

Exhibit No.	Description
99.1	Letter to Shareholders

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 7, 2016

BIOTRICITY INC.

By: /s/ Waqaas Al-Siddiq
Waqaas Al-Siddiq
Chief Executive Officer

Dear Shareholders,

It has been a while since my last communication, so I wanted to provide an update on our progress. By most accounts, we have progressed rapidly and are executing our plans successfully. On the business side of things:

1. We have begun building out our Business Development and Sales team with individuals who have vast experience in the MCT and cardiac monitoring market. We have made significant progress on the telecom side with AT&T becoming our preferred partner for telecom services for our solution. We are also building out additional strategic partnerships.

2. We have a strong advisory board and board of directors that we will continue to build out over the next year.

3. Our product has gotten great feedback from the small sample size of Cardiologists and Electrophysiologists that we have spoken to and we believe we will do very well once we enter the market. We have received great press and media coverage. The company has been featured twice in Forbes, in CB Insights, and in other major outlets. We aim to be a major thought leader in our industry.

On the regulatory side we are moving along well:

1. We created our own variation of the ECG software and have received clearance on that. The clearance was received on October 13 for a Class II medical product, which speaks to the strong team we have here.

2. We are in the middle of preparing our FDA filing for the hardware and expect to get this filed by the end of 2016.

Regarding corporate matters, we have been working on capital, developing an audience for the company, and getting our S-1 filing complete. Some details:

1. We did a bridge capital round over the summer because summers are typically very slow. This was successful and oversubscribed.

2. We are working on establishing a larger audience for our news. If you know anyone that is interested in healthcare related news, please let us know and we will happily add them to our mailing list. Alternatively, you can contact us at social@biotricity.com

3. With regards to our former iMedical shareholders, we are working hard on getting the S-1 effective with the SEC. Although this can be an arduous process and we cannot control how long it will take, we have made it a priority.

As always, please contact us if you have any questions.

Thank you for your continued support,

Waqas

Chairman and CEO